id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-303135-rx21ajiw	Jian, Li	Perspective: COVID-19, implications of nasal diseases and consequences for their management	2020-05-01		.txt	text/plain	1723	82	47	This leads us to the question whether treatment in patients with allergic rhinitis, normally INCS, or in severe patients with CRSwNP, nowadays including biologics to suppress type 2 immune reactions, should be continued in case of a SARS-CoV-2 infection. SARS-CoV-2 may also infect patients with severe asthma and CRSwNP, who might be under treatment with a type 2 biologic drug such as dupilumab, omalizumab, or mepolizumab. However, we begin to recognize that diseases of the upper airways or their management by corticosteroids and biologics do not seem to increase the risk of infection nor the risk for severe COVID-19. In research perspective, because the airway passage of nose and nasopharynx is the main entry for respiratory viruses including the SARS-CoV 2, the expression and its regulation of the ACE2 receptor and the TMPRSS2 protease are key topics for research and targets for interventions. SARS-CoV-2 entry genes are most highly expressed in nasal goblet and ciliated cells within human airways	./cache/cord-303135-rx21ajiw.txt	./txt/cord-303135-rx21ajiw.txt